Drugs / Finotonlimab
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07040072 | Oct 2025 → Jun 2027 expected | head and neck squamous cell carcinoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05552807 | Jun 2022 → Sep 2023 | head and neck squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04229537 | Mar 2020 → Aug 2022 | colorectal cancer, esophageal squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03821363 | Dec 2018 → Jul 2020 | neoplasm | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07618624 | Apr 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Sun Yat-sen University | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06986785 | Jun 2025 → May 2027 expected | hepatocellular carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT04146181 | Oct 2019 → Jun 2021 | head and neck squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04560894 | Nov 2020 → Apr 2024 | hepatocellular carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07509099 | Sep 2026 → Sep 2031 expected | head and neck squamous cell carcinoma | Ji Dongmei | Recruiting | No outcome recorded |
| Phase 3 | NCT04146402 | Dec 2019 → Jan 2022 | head and neck squamous cell carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04171284 | Oct 2019 → Feb 2023 | non-small cell squamous lung carcinoma | Sinocelltech Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase not applicable1 trial | ||||||
| — | NCT07009470 | Feb 2025 → Apr 2028 expected | hepatocellular carcinoma | Tongji Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Finotonlimab | “Here a randomized, double-blind phase 3 trial evaluated the efficacy and safety of finotonlimab (SCT-I10A), a programmed cell death 1 (PD-1) monoclonal antibody, combined with...” PMID 38942993 ↗ Jun 20247“Patients were randomized 2:1 to finotonlimab plus docetaxel group (finotonlimab plus docetaxel) and docetaxel group (placebo plus docetaxel) for up to 6 cycles, followed by...” PMID 40386729 ↗ Apr 2025 “We aimed to assess the tolerability and efficacy of finotonlimab (an anti-programmed cell death protein-1 antibody) in combination with SCT510, a bevacizumab biosimilar, versus...” PMID 40769977 ↗ Aug 2025 |
| Known as | SCT-I10A | “Finotonlimab (SCT-I10A) is a recombinant humanized anti-PD-1 monoclonal antibody approved by NMPA for first-line R/M HNSCC in combination with platinum-based chemotherapy.” NCT07618624 ↗4“SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.” NCT04146181 ↗ |
| Action | Inhibit | “anti-PD-1” NCT07009470 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti- PD-1 monoclonal antibody” NCT03821363 ↗ |
| Route | Intravenous | “200 mg intravenous (IV)” NCT04146181 ↗ |
| Target | PDCD1 | “anti-programmed cell death 1 antibody (SCT-I10A)” PMID 40819238 ↗ Aug 2025 |